What Is Sickle Cell Disease? A Complete Guide for Patients and Families

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified hematologist or healthcare provider for guidance specific to your situation.

If you or someone you love has been diagnosed with sickle cell disease, you've likely had to explain it — over and over — to people who simply don't understand. You've probably sat in waiting rooms, navigated skeptical doctors, and searched for answers that felt real, not clinical. This guide is written for you, and for families, caregivers, teachers, and anyone who wants to understand sickle cell disease with the depth and honesty it deserves.

What Is Sickle Cell Disease?

Sickle cell disease (SCD) is an inherited blood disorder that fundamentally changes the shape, behavior, and lifespan of red blood cells. Normally, red blood cells are round and flexible — they bend and squeeze through even the smallest capillaries, delivering oxygen to every organ and tissue in the body. In SCD, this process breaks down at the molecular level.

The disease is caused by a mutation in the HBB gene, which provides instructions for producing beta-globin — one of the two proteins that form hemoglobin, the oxygen-carrying molecule inside red blood cells. In SCD, a single point mutation substitutes glutamic acid for valine at position 6 of the beta-globin chain, producing an abnormal form called hemoglobin S (HbS).

When oxygen levels drop — during illness, exercise, cold exposure, dehydration, or stress — HbS molecules inside the red blood cell polymerize: they form long, rigid chains that push against the cell membrane and force the cell into a crescent or "sickle" shape. These deformed cells are the source of virtually every complication in the disease.

The Genetics of Sickle Cell Disease

SCD follows an autosomal recessive inheritance pattern. This means a person must inherit one copy of the HbS mutation from each parent to develop sickle cell disease. People who inherit only one copy of the mutation — one from an affected parent, one normal copy from the other — have sickle cell trait (SCT), not sickle cell disease. Sickle cell trait is generally not a disease: people with SCT usually have no symptoms and live normal lives, but they are carriers who can pass the mutation to their children.

When both parents carry sickle cell trait, each pregnancy has:

• A 25% chance of sickle cell disease (inheriting HbS from both parents)
• A 50% chance of sickle cell trait (inheriting HbS from one parent)
• A 25% chance of normal hemoglobin (inheriting normal copies from both parents)

The most common form of SCD is hemoglobin SS disease (HbSS), often called sickle cell anemia — the most severe form. Other forms include HbSC disease (inheriting one HbS and one HbC mutation), HbS beta-thalassemia, and rarer variants like HbSD and HbSE. Disease severity varies significantly across these genotypes.

How SCD Damages the Body

Sickled red blood cells create damage through two primary mechanisms: vascular occlusion (blocking blood flow) and hemolysis (premature destruction). Both processes are occurring constantly in people with SCD — not just during crises.

Vaso-Occlusive Crisis (VOC)

When sickled cells accumulate in small blood vessels, they cause blockages that cut off oxygen to the surrounding tissue — a vaso-occlusive crisis. This is the most common and characteristic manifestation of SCD. The resulting tissue hypoxia causes intense pain, most often in the bones (particularly the long bones of the arms and legs), chest, abdomen, and lower back. Pain crises are the leading cause of emergency department visits and hospitalizations in SCD. Research documents that VOC pain is among the most severe pain measurable — comparable to post-surgical pain — yet SCD patients consistently receive undertreated pain management in emergency settings. For a detailed account of what this pain feels like and how to manage it, see our guide on What Does Sickle Cell Pain Feel Like?

Chronic Anemia

Normal red blood cells survive about 120 days. Sickled cells are fragile and typically survive only 10–20 days before they rupture (hemolyze). The bone marrow cannot produce replacement cells fast enough, resulting in chronic anemia — low red blood cell count and reduced oxygen-carrying capacity throughout the body. Chronic anemia causes persistent fatigue, pallor, dizziness, and shortness of breath that affect daily functioning even between pain episodes.

Acute Chest Syndrome (ACS)

ACS is one of the most dangerous complications of SCD and the leading cause of death. It occurs when sickled cells, fat emboli from bone marrow, or infection cause inflammation and blockage in the small blood vessels of the lungs. Symptoms include new infiltrates on chest X-ray, fever, chest pain, and declining oxygen saturation. ACS requires immediate hospitalization and intensive treatment. People with SCD and any new chest pain accompanied by fever or difficulty breathing should seek emergency care immediately — this is not a symptom to wait out at home.

Stroke

People with SCD have a significantly elevated stroke risk compared to the general population. Overt stroke — with sudden neurological deficit — occurs in approximately 11% of people with HbSS disease before age 20. Silent stroke (causing brain injury without obvious symptoms) is even more common, affecting up to 35% of people with SCD by adulthood. Transcranial Doppler (TCD) ultrasound screening, recommended beginning at age 2, identifies children at high risk for stroke, who can then begin prophylactic blood transfusion therapy that dramatically reduces risk.

Organ Damage

Because sickling can occur in any blood vessel, virtually every organ is at risk over time. The spleen is typically damaged — and often functionally absent — by early childhood in people with HbSS disease, due to repeated sickling episodes. This causes hyposplenism, dramatically increasing vulnerability to life-threatening bacterial infections, particularly from encapsulated organisms like Streptococcus pneumoniae. The kidneys, liver, eyes, heart, and bone are all affected by cumulative vascular damage over years of disease. Avascular necrosis (AVN) of the hip and shoulder joints — caused by disrupted blood supply to bone tissue — affects a significant proportion of adults with SCD and may ultimately require joint replacement surgery.

Who Is Affected by Sickle Cell Disease?

SCD is the most common serious inherited blood disorder in the world. It is most prevalent in populations from sub-Saharan Africa, the Mediterranean, Middle East, and India — regions where malaria has historically been endemic. The sickle cell trait provides partial protection against severe malaria, which is why the mutation persisted and became common in these populations through evolutionary selection.

Globally, approximately 300,000 children are born with SCD each year. In the United States, about 100,000 people live with SCD — the vast majority of African American descent. SCD affects approximately 1 in 365 Black Americans. In parts of sub-Saharan Africa, 2–3% of all births are affected by SCD. Despite its prevalence, SCD has historically received far less research funding and public health attention relative to its disease burden.

Newborn Screening: The Critical First Step

Newborn screening for SCD is now universal in the United States and many other countries. A heel prick blood spot taken in the first days of life identifies infants with SCD before symptoms develop. This matters enormously: the first years of life are the highest-risk period for life-threatening infections and splenic sequestration crises, and early intervention — prophylactic penicillin, pneumococcal vaccination, parental education, and connection to a comprehensive care center — dramatically reduces early mortality.

In sub-Saharan Africa, where 80% of the world's SCD births occur, newborn screening coverage remains limited and highly variable. This is one of the primary reasons that over 50% of African children born with SCD die before age 5 — a preventable tragedy with available interventions.

Treatment Options in 2026

The treatment landscape for SCD has expanded significantly in recent years, though access remains deeply inequitable:

Hydroxyurea

Hydroxyurea (hydroxycarbamide) was the first FDA-approved treatment for SCD and remains the most widely used disease-modifying drug. It works primarily by stimulating fetal hemoglobin (HbF) production. Since HbF cannot participate in the polymerization process that causes sickling, higher HbF levels reduce the proportion of HbS available to sickle, decreasing crisis frequency and severity. Clinical trials demonstrated approximately 50% reduction in hospitalizations among hydroxyurea responders. Hydroxyurea is now recommended for all people with HbSS or HbS beta0-thalassemia beginning at 9 months of age, regardless of disease severity.

Gene Therapy: A Potential Cure

Two gene therapies received FDA approval in December 2023: Casgevy (exagamglogene autotemcel, from Vertex/CRISPR Therapeutics), the first CRISPR-based therapy approved for any disease, priced at $2.2 million; and Lyfgenia (lovotibeglogene autotemcel, from bluebird bio), priced at $3.1 million. Both are one-time treatments that modify or augment hemoglobin production at the genetic level. Early results show dramatic reductions in vaso-occlusive crises. The extraordinary cost makes these therapies inaccessible to most people globally, highlighting the access gap between those with SCD in high-income countries and the 90% of the world's SCD population living elsewhere.

Complementary Wellness and Daily Management

Medical treatment is the foundation of SCD care, but daily wellness practices meaningfully affect quality of life and crisis frequency. The evidence-based pillars of daily SCD management include consistent hydration, anti-inflammatory nutrition, temperature management, stress reduction, adequate sleep, and — for some families — botanical supplementation. See our complete guide to anti-sickling nutrition for specific dietary recommendations backed by current evidence. See the science behind HalfMoon Labs' formula.

Frequently Asked Questions

Q: Is sickle cell disease the same as sickle cell trait?
No. Sickle cell trait means you carry one copy of the HbS mutation — you are a carrier but typically have no symptoms and normal life expectancy. Sickle cell disease means you inherited two copies of HbS (or HbS plus another hemoglobin mutation), and you have the full disease with its complications.

Q: Can sickle cell disease be cured?
Yes — but access to cures is limited. Matched sibling stem cell transplant can cure SCD in selected patients. The two new gene therapies (Casgevy and Lyfgenia) approved in 2023 have produced functional cures in clinical trials, but at $2–3 million per treatment, they are inaccessible to most people globally.

Q: What is the life expectancy of someone with sickle cell disease?
In the United States, median life expectancy for people with HbSS disease is approximately 52–58 years. This is substantially lower than the general population but dramatically improved from the 1970s when most children did not survive to adulthood.

Q: How do I know if I carry the sickle cell trait?
A simple blood test — hemoglobin electrophoresis or HPLC — can identify sickle cell trait. Adults can request this test through their primary care physician. Genetic counseling is recommended for couples where both partners carry sickle cell trait.

Q: Does diet affect sickle cell disease?
Yes, meaningfully. Anti-inflammatory nutrition — omega-3 fatty acids, dark leafy greens, papaya, berries, adequate hydration — supports red blood cell health and reduces systemic inflammation. See our Sickle Cell Diet Plan for comprehensive guidance.

Key Takeaways

• SCD is caused by a point mutation in the HBB gene producing hemoglobin S, which causes red blood cells to deform under low-oxygen conditions
• It follows an autosomal recessive pattern; sickle cell trait carries one copy and is generally asymptomatic
• Main complications: vaso-occlusive crises, chronic anemia, acute chest syndrome, stroke, and organ damage
• ~300,000 children born globally with SCD each year — 80% in sub-Saharan Africa
• Hydroxyurea is the cornerstone therapy; gene therapies approved in 2023 offer potential cures at extraordinary cost
• Daily wellness practices — hydration, anti-inflammatory nutrition, stress management — meaningfully affect outcomes

External Sources:
NIH NHLBI: Sickle Cell Disease
Sickle Cell Disease Association of America
CDC: Sickle Cell Disease Data

Related Reading:
What Does Sickle Cell Pain Feel Like?
The Sickle Cell Diet Plan
The Science Behind HalfMoon Labs

This article is for educational purposes only. HalfMoon Labs products are not intended to diagnose, treat, cure, or prevent any disease. Always work with your hematologist and care team.